A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia

Copenhagen University Hospital at Herlev

Status and phase

Unknown

Phase 2

Conditions

Polycythemia Vera

Essential Thrombocythemia

Treatments

Drug: HDAC inhibitor (MK-0683)

Study type

Interventional

Funder types

Other

Identifiers

NCT00866762

MK-0683/092-0

Details and patient eligibility

About

The aim of the present study is to evaluate the efficacy and safety of MK-0683 in the treatment of PV and ET. This agent has most recently been shown to be a potent inhibitor of the autonomous proliferation of haematopoietic cells of PV and ET patients carrying the JAK2 V617F mutation. Accordingly, it may be anticipated that MK-0683 - by decreasing the JAK2 allele burden - may influence clonal myeloproliferation and in vivo granulocyte, platelet and endothelial activation , which are considered to be major determinants of morbidity and mortality ( thrombosis, bleeding, extramedullary haematopoiesis , myelofibrosis ) in these disorders. The effects of MK-0683 at the molecular level will be studied by global/ focused gene expression profiling, epigenome profiling and proteomics.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female patient > 18 years of age AND
A confirmed diagnosis of PV AND
Biochemical evidence of active disease as defined by:
- a need for phlebotomy within last 3 months
- a leukocyte count > 10 x 10^9/L in the absence of infection or inflammation (normal CRP) and/or (PV/ET)
- a platelet count > 450 x 10^9/L in the absence of infection or inflammation (normal CRP)(PV/ET) OR
Male or female patient > 18 years of age AND
A confirmed diagnosis of ET AND
Biochemical evidence of active disease as defined by *a platelet count > 450 x 10^9/L in the absence of infection or inflammation

Inclusion Criteria for both PV and ET:

Newly diagnosed or previously treated patient in chronic phase OR
Advanced phase PV or ET as defined by blasts of > 1 x 10^9/L in the peripheral blood and/or white cell count > 30 x 10^9/L OR
Resistant or refractory PV or ET as defined by haemoglobin < 10.5 gm/dl with a platelet count > 600 x 10^9/L on current therapy OR
Cycling platelet counts on therapy OR
Intolerant to other therapies defined by patients with PV or ET who have side effects on current therapies preventing continuation (leg ulcers on hydroxycarbamide, unacceptable fatigue etc on interferon)

Exclusion criteria

A platelet count > 1500 x 10^9/L (a need for cytoreduction in platelet count)
Patients of childbearing potential without a negative pregnancy test prior to initiation of study drug
Women who are breast feeding
Males and females not using contraceptives if sexually active.
EGOC Performance status Score > or = 3
Serum creatinine more than 2 x's teh ULN
Total serum bilirubin more than 1.5 x's the ULN
Serum AST/ALT more than 3 x's the ULN
Interferon alpha within 1 week of day 1
Hydroxycarbamide within 1 week of day 1
Anagrelide within 1 week of day 1
Valproic acid (as an anticonvulsant) within 28 days of day 1
Any other investigational drug within 28 days of day 1
Active HIV, HBV or HCV infection
Any serious concomitant disease or circumstances that could limit compliance with the study, including but not limited to the following: CTCAE grade 3-4 cardiac general & arrhythmia, or psychiatric or social conditions that may interfere with patient compliance.
Any prior malignancy with the exception of cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or other localized malignancy that has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed to be at low risk for recurrence by his/her treating physician.
Patient has a known allergy or hypersensitivity to study drug.